EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
The interim results of the Phase III clinical trial of EirGenix breast cancer biosimilar, EG12014 (a proposed trastuzumab biosimilar) have been published at the 2021 San Antonio Breast Cancer Symposium (SABCS21). The primary efficacy endpoint, pCR at the time of surgery, demonstrated equivalence of EG12014 and Herceptin. EG12014 has also demonstrated a comparable safety profile. Abstract number: P2-13-17.